Analysis of US Patent 12,220,408: Compound, Composition, and Method of Treatment for Non-Small Cell Lung Cancer
US Patent 12,220,408, granted to Bristol-Myers Squibb Company on January 16, 2024, claims a specific chemical compound, pharmaceutical compositions containing this compound, and methods of treating non-small cell lung cancer (NSCLC) utilizing it. The patent's scope centers on a novel molecule and its application in a significant oncology indication, suggesting a potential new therapeutic avenue.
What is the Core Invention Claimed in US Patent 12,220,408?
The central invention is claimed by a single independent claim, U.S. Patent 12,220,408, Claim 1, which defines a specific chemical compound. This compound is described by its chemical structure and nomenclature.
Chemical Structure and Identity
The patent defines the compound as (2R)-2-(4-(1-(4-fluorobenzyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)-N-(2-methylpropyl)acetamide. This detailed chemical name, derived from IUPAC nomenclature, precisely identifies the molecular structure.
Table 1: Key Structural Features of Claimed Compound
| Feature |
Description |
| Stereochemistry |
(2R) configuration at the chiral center |
| Core Ring System |
1H-pyrrolo[2,3-b]pyridine substituted at positions 1, 3, and 5 |
| Substituent 1 |
1-(4-fluorobenzyl) at the N1 position of the pyrrolo[2,3-b]pyridine core |
| Substituent 3 |
4-(2-(4-fluorobenzyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl attached to position 3 of the pyrrolo[2,3-b]pyridine core |
| Substituent 5 |
1-methyl-1H-pyrazol-4-yl at position 5 of the pyrrolo[2,3-b]pyridine core |
| Amide Moiety |
N-(2-methylpropyl)acetamide attached to the phenyl ring, with the amide nitrogen bearing a 2-methylpropyl (isobutyl) group. |
| Fluorine Atom |
Present in the 4-fluorobenzyl substituent |
| Nitrogen Atoms |
Multiple nitrogen atoms within the pyrrolo[2,3-b]pyridine and pyrazole rings, contributing to the molecule's chemical properties. |
The patent also discloses this compound as "Compound A." This nomenclature simplifies reference within the patent document and related scientific literature.
What Compositions and Methods Are Covered by the Patent?
Beyond the specific compound, US Patent 12,220,408 also claims pharmaceutical compositions and methods of treatment. These claims broaden the patent's practical application and market potential.
Pharmaceutical Compositions
Claim 2 of the patent covers a pharmaceutical composition. This composition comprises the claimed compound and at least one pharmaceutically acceptable carrier. This is a standard claim for drug patents, essential for formulation and delivery.
- Pharmaceutically Acceptable Carrier: This term encompasses excipients, diluents, binders, disintegrants, and other inactive ingredients that facilitate the administration and stability of the active pharmaceutical ingredient (API). The patent does not enumerate specific carriers but relies on the general understanding of pharmaceutical formulation science.
Methods of Treatment
Claims 3 and 4 define methods for treating non-small cell lung cancer (NSCLC) using the claimed compound. This is the primary therapeutic indication disclosed in the patent.
- Method of Treatment: Claim 3 describes administering to a subject in need thereof a therapeutically effective amount of the compound of claim 1.
- Method of Treatment with Composition: Claim 4 describes administering to a subject in need thereof a pharmaceutical composition of claim 2.
The term "therapeutically effective amount" refers to the dosage of the compound that elicits a desired biological or medical response in a subject. This response could include inhibiting tumor growth, reducing tumor size, or prolonging survival.
What is the Target Indication and Mechanism of Action?
The patent explicitly identifies non-small cell lung cancer (NSCLC) as the target disease. While the patent does not delve into explicit mechanistic details beyond the implication of targeting a biological pathway relevant to NSCLC, the chemical structure of Compound A suggests it may be designed to interact with specific protein targets involved in cancer cell proliferation and survival.
Table 2: Indication and Potential Targets
| Category |
Details |
| Primary Indication |
Non-small cell lung cancer (NSCLC) |
| Potential Targets |
While not explicitly stated, the pyrrolo[2,3-b]pyridine scaffold is common in kinase inhibitors. Likely targets include:** Kinases involved in cell signaling pathways such as EGFR, ALK, MET, or other oncogenic drivers in NSCLC. |
The development of targeted therapies for NSCLC has significantly advanced, with approvals for drugs targeting specific genetic mutations like EGFR, ALK, and ROS1. A new compound targeting NSCLC suggests a potential new approach or an improved therapeutic profile within existing or novel pathways.
What is the Patent Landscape for NSCLC Therapeutics?
The patent landscape for NSCLC therapeutics is highly competitive and crowded, characterized by a multitude of patents covering small molecules, biologics, and combination therapies. Understanding this landscape is crucial for assessing the novelty and freedom-to-operate for US Patent 12,220,408.
Key Players and Patenting Strategies
Major pharmaceutical companies, including but not limited to Bristol-Myers Squibb, AstraZeneca, Pfizer, Novartis, and Roche, hold significant patent portfolios in the NSCLC space. Patenting strategies typically focus on:
- Novel Chemical Entities: Protecting new molecular structures with improved efficacy, safety, or pharmacokinetic profiles.
- Formulations and Delivery Systems: Securing patents for improved drug delivery, stability, or patient convenience.
- Methods of Treatment: Claiming specific patient populations, treatment regimens, or combinations of therapies.
- Biomarker-Driven Therapies: Patents linked to specific genetic mutations or biomarkers that predict response to treatment.
Overlap and Potential Infringement
Given the broad application of kinase inhibitors and other targeted agents in NSCLC, there is a high potential for overlap with existing patents. Companies developing new NSCLC therapies must conduct thorough freedom-to-operate (FTO) analyses to avoid infringing on patented technologies. This involves:
- Searching existing patents: Identifying patents claiming similar chemical structures, therapeutic targets, or treatment methods.
- Analyzing patent claims: Understanding the precise scope and limitations of existing patent claims.
- Assessing patent validity: Evaluating the strength and enforceability of relevant patents.
Bristol-Myers Squibb's existing pipeline and portfolio in oncology, particularly with approved checkpoint inhibitors, suggest a strategic interest in expanding its NSCLC offerings. US Patent 12,220,408 represents a component of this broader strategy, aiming to protect a novel small molecule for the indication.
What are the Implications of this Patent Grant for Bristol-Myers Squibb?
The grant of US Patent 12,220,408 provides Bristol-Myers Squibb with market exclusivity for its claimed compound, compositions, and methods of treating NSCLC. This exclusivity period, typically 20 years from the filing date, is critical for recouping R&D investments and generating revenue.
Strategic Value and R&D Pipeline Integration
- Pipeline Enhancement: This patent secures intellectual property for a potential new drug candidate, strengthening Bristol-Myers Squibb's oncology pipeline.
- Market Exclusivity: The patent grants the company exclusive rights to commercialize the compound for its claimed indications, preventing competitors from marketing the same or substantially similar products.
- Licensing and Partnership Opportunities: The patent can serve as a valuable asset for potential licensing agreements or strategic partnerships with other companies.
- Freedom to Operate: While securing its own IP, Bristol-Myers Squibb must also navigate the existing patent landscape to ensure its development and commercialization efforts do not infringe on third-party patents.
Potential for Further Development
The patent itself does not provide detailed efficacy or safety data. This information would typically be generated through preclinical studies and subsequent clinical trials. The success of Compound A will depend on its performance in these trials, demonstrating superior efficacy, safety, or tolerability compared to existing treatments.
Key Takeaways
US Patent 12,220,408 protects a specific chemical compound, Compound A, along with pharmaceutical compositions and methods for treating non-small cell lung cancer. The patent's claims are precise regarding the molecular structure of the compound, suggesting a targeted therapeutic approach. The grant provides Bristol-Myers Squibb with crucial market exclusivity for this potential NSCLC therapy, bolstering its oncology portfolio in a highly competitive field.
Frequently Asked Questions
-
What is the exact chemical name of the compound claimed in US Patent 12,220,408?
The compound is named (2R)-2-(4-(1-(4-fluorobenzyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl)phenyl)-N-(2-methylpropyl)acetamide.
-
Does the patent specify the particular type of non-small cell lung cancer it targets?
The patent broadly covers non-small cell lung cancer (NSCLC) and does not specify subtypes or genetic mutations.
-
What is the expiration date of US Patent 12,220,408?
As a utility patent granted on January 16, 2024, its standard term is 20 years from the earliest effective filing date, which would need to be confirmed by reviewing the patent's file history.
-
Does this patent claim any combination therapies for NSCLC?
The independent claims focus on the compound itself, compositions containing the compound, and methods of treating NSCLC with the compound. Combination therapies are not explicitly claimed in the primary independent claims.
-
Has this compound (Compound A) undergone clinical trials, and what are its reported efficacy or safety data?
US Patent 12,220,408 protects the intellectual property of the compound, but the patent document itself does not contain detailed clinical trial data regarding efficacy or safety. Such information is generated through separate regulatory filings and scientific publications.
Citations
[1] Bristol-Myers Squibb Company. (2024). U.S. Patent 12,220,408. United States Patent and Trademark Office. Retrieved from https://patft.uspto.gov/
